HMN14 (Not yet branded)
Other Medications
Description
HMN14 is a humanized monoclonal antibody that targets the CEACAM5 antigen (carcinoembryonic antigen, CEA) commonly overexpressed on colorectal cancer cells. It has been developed as both an unconjugated antibody and as a radioimmunotherapeutic agent when labeled with yttrium-90 (90Y-hMN14). The medication is designed to deliver targeted therapy to CEA-positive colorectal tumors, with particular focus on treating patients with limited residual disease following surgical resection.
Mechanism of Action
HMN14 binds specifically to the CEACAM5 (CEA) protein found on the surface of colorectal cancer cells. When conjugated with yttrium-90, the antibody delivers targeted radioactive therapy directly to tumor cells, causing DNA damage and cell death through beta radiation emission while minimizing exposure to healthy tissues.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.